High mobility group box 1 and tumor growth factor β: useful biomarkers in pediatric patients receiving peritoneal dialysis

Figures & data

Table 1. Clinical characteristics and laboratoristic data of cohort study.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Age, years	5	4	16	4	9	16
Gender, M/F	M	M	F	F	F	M
Dialysis duration, months	32	21	66	27	44	56
Creatinine, mg/dL	3.5	3.2	3.6	2.8	4.1	4.3
Urea, mg/dL	43	46	48	39	58	62
Systolic blood pressure	100	110	100	120	110	150
Diastolic blood pressure	50	60	70	90	70	100
UF	100	948	1095	989	435	1300
Peritonitis data
Gram POS	X	–	X	–	–	–
Gram NEG	–	–	–	–	–	–
Fungi	–	–	–	–	–	–
Negative cultures	–	X	–	X	–	–
Days until resolution	5	4	3	5	–	–
HMGB1 and WBC trend	T0	T-pre	T1		T-end
sHMGB1, ng/mL	9.5 ± 1.0	32.1 ± 3.3	64 ± 3.6		36 ± 2.5
pHMGB1, ng/mL	6.9 ± 3.6	35.8 ± 6.9	70 ± 5.3		30.5 ± 7.0
sWBC, cells/mm^3	4796 ± 325	5008 ± 303.4	14,750 ± 1109		5500 ± 470.4
pWBC, cells/mm^3	8.3 ± 3.3	44.6 ± 10.5	512 ± 331.6		10.5 ± 4.7

UF: Ultrafiltration; sHMGB1: serum high mobility group box 1; pHMGB1: peritoneal high mobility group box 1; sWBC: serum white blood cells; pWBC: peritoneal white blood cells.

Figure 1. High mobility group box 1 (HMGB1) and white blood cell (sWBC) count in sera and peritoneal effluent before, during, and after a peritonitis event.

Figure 2. Univariate correlation between transforming growth factor (TGF)-β levels and dialysate/plasmatic creatinine values.